Cipla share price fell over 5 percent in the early trade on February 26 after the company received a warning letter from the USFDA.
The company has received a warning letter from the United States Food and Drug Administration (USFDA) for the company's Goa manufacturing facility.
The inspection conducted from 16-27 September 2019.
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
At 09:18 hrs Cipla was quoting at Rs 414.05, down Rs 11.30, or 2.66 percent on the BSE.
The share touched its 52-week high Rs 585.50 and 52-week low Rs 389.55 on 27 May, 2019 and 11 October, 2019, respectively.
Currently, it is trading 29.28 percent below its 52-week high and 6.29 percent above its 52-week low.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
